For patients with R/R DLBCL
who are not eligible for or refuse ASCT 1
who are not eligible for or refuse ASCT 1
MINJUVI® + Lenalidomide
right after the first relapse
right after the first relapse
Videos
Short-Video-Interviews about Tafasitamab + Lenalidomid for patients with R/R DLBCL
Renowned Swiss experts talk in their online interviews, about their personal experiences with Tafasitamab and about the RWE data presented at the ASH Congress (2023).
RWE data and personal experiences with Tafasitamab
Prof. Dr. med. Christoph Renner
Professional Information MINJUVI®
Scientific Information MINJUVI®
Patient Information MINJUVI® – Post-Prescription Brochures
- In 2L: More than 50 % CR- rate2,a
- More than 50 % survival probability after 5 years in 2L2
- Chemotherapy-free „off-the-shelf“ immunotherapy with a favorable safety profile2
Indication:1
MINJUVI® is indicated in combination with lenalidomide followed by MINJUVI® monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least one line of systemic CD20-targeted antibody therapy who are not eligible for autologous stem cell transplantation (ASCT).1
